Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingremitting multiple sclerosis: a prospective, non-randomized pilot study

被引：43
作者：
Portaccio, E. [1 ]
Stromillo, M. L. [2 ]
Goretti, B. [1 ]
Hakiki, B. [1 ]
Giorgio, A. [2 ]
Rossi, F. [2 ]
De Leucio, A. [2 ]
De Stefano, N. [2 ]
Amato, M. P. [1 ]
机构：
[1] Univ Florence, Dept Neurol, I-50134 Florence, Italy
[2] Univ Siena, Dept Neurol, I-53100 Siena, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2013年 / 20卷 / 06期
关键词：
atrophy; cognitive impairment; interferon beta; magnetic resonance; multiple sclerosis; natalizumab; BRIEF REPEATABLE BATTERY; INTERFERON BETA-1A; IMPAIRMENT; DISABILITY; RELEVANCE; MRI; MS;
D O I：
10.1111/j.1468-1331.2012.03882.x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background and purpose The development of treatment strategies for cognitive impairment in multiple sclerosis (MS) is still in its infancy. The objective of this prospective, non-randomized, pilot study was to assess the possible efficacy of treatment with natalizumab in comparison with interferon beta (IFNB) in a group of relapsingremitting patients with MS. Methods We included 12 patients treated with natalizumab and 14 with IFNB. At baseline and at follow-up, cognitive functioning was assessed through Rao's Brief Repeatable Battery. All the patients underwent brain MR study with the assessment of T2 lesion volumes, neocortical volume, normalized brain volume and percentage brain volume change (PBVC). Evolution of cognitive performance was assessed using available normative data for the Italian population. Treatment comparisons were assessed through the MannWhitney U-test, anova for repeated measures and linear multivariate regression analyses. Results After a mean follow-up of 1.5years, the mean number of neuropsychological tests with a deteriorating performance was significantly lower in patients treated with natalizumab (0.7 +/- 0.7 vs. 1.7 +/- 1.4; P=0.031). Likewise, PBVC was significantly lower in natalizumab-treated subjects than that observed in patients treated with IFNB (0.51%+/- 0.47% vs. 1.18%+/- 0.98%; P=0.050). Concluion Our results suggest a potential beneficial effect of natalizumab therapy on cognitive functioning in MS, possibly mediated by a reduction of brain atrophy.
引用
收藏
页码：986 / 990
页数：5
相关论文
共 25 条
[1]   The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population [J].
Amato, M. P. ;
Portaccio, E. ;
Goretti, B. ;
Zipoli, V. ;
Ricchiu, L. ;
De Caro, M. F. ;
Patti, F. ;
Vecchio, R. ;
Sorbi, S. ;
Trojano, M. .
MULTIPLE SCLEROSIS, 2006, 12 (06) :787-793
[2]   Association of MRI metrics and cognitive impairment in radiologically isolated syndromes [J].
Amato, M. P. ;
Hakiki, B. ;
Goretti, B. ;
Rossi, F. ;
Stromillo, M. L. ;
Giorgio, A. ;
Roscio, M. ;
Ghezzi, A. ;
Guidi, L. ;
Bartolozzi, M. L. ;
Portaccio, E. ;
De Stefano, N. .
NEUROLOGY, 2012, 78 (05) :309-314
[3]   Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study [J].
Amato, Maria P. ;
Portaccio, Emilio ;
Goretti, Benedetta ;
Zipoli, Valentina ;
Iudice, Alfonso ;
Della Pina, Dario ;
Malentacchi, Gianmichele ;
Sabatini, Simonetta ;
Annunziata, Pasquale ;
Falcini, Mario ;
Mazzoni, Monica ;
Mortilla, Marzia ;
Fonda, Claudio ;
De Stefano, Nicola .
MULTIPLE SCLEROSIS, 2010, 16 (12) :1474-1482
[4]  
Amato Maria Pia, 2008, Expert Rev Neurother, V8, P1585, DOI 10.1586/14737175.8.10.1585
[5]   Cognitive dysfunction in early-onset multiple sclerosis - A reappraisal after 10 years [J].
Amato, MP ;
Ponziani, G ;
Siracusa, G ;
Sorbi, S .
ARCHIVES OF NEUROLOGY, 2001, 58 (10) :1602-1606
[6]   Effect of interferon-beta-1b on cognitive functions in multiple sclerosis [J].
Barak, Y ;
Achiron, A .
EUROPEAN NEUROLOGY, 2002, 47 (01) :11-14
[7]   Evaluating and reducing the impact of white matter lesions on brain volume measurements [J].
Battaglini, Marco ;
Jenkinson, Mark ;
De Stefano, Nicola .
HUMAN BRAIN MAPPING, 2012, 33 (09) :2062-2071
[8]   Evidence of early cortical atrophy in MS relevance to white matter changes and disability [J].
De Stefano, N ;
Matthews, PM ;
Filippi, M ;
Agosta, F ;
De Luca, M ;
Bartolozzi, ML ;
Guidi, L ;
Ghezzi, A ;
Montanari, E ;
Cifelli, A ;
Federico, A ;
Smith, SM .
NEUROLOGY, 2003, 60 (07) :1157-1162
[9]   The contribution of MRI in assessing cognitive impairment in multiple sclerosis [J].
Filippi, M. ;
Rocca, M. A. ;
Benedict, R. H. B. ;
DeLuca, J. ;
Geurts, J. J. G. ;
Rombouts, S. A. R. B. ;
Ron, M. ;
Comi, G. .
NEUROLOGY, 2010, 75 (23) :2121-2128
[10]  
Fischer JS, 2000, ANN NEUROL, V48, P885, DOI 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO
123